Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Archive ouverte

Vanhersecke, Lucile | Brunet, Maxime | Guégan, Jean-Philippe | Rey, Christophe | Bougouin, Antoine | Cousin, Sophie | Le Moulec, Sylvestre | Besse, Benjamin | Loriot, Yohann | Larroquette, Mathieu | Soubeyran, Isabelle | Toulmonde, Maud | Roubaud, Guilhem | Pernot, Simon | Cabart, Mathilde | Chomy, Francois | Lefevre, Corentin | Bourcier, Kevin | Kind, Michele | Giglioli, Ilenia | Sautes-Fridman, Catherine | Velasco, Valerie | Courgeon, Felicie | Oflazoglu, Ezoglin | Savina, Ariel | Marabelle, Aurelien | Soria, Jean-Charles | Bellera, Carine | Sofeu, Casimir | Bessede, Alban | Fridman, Wolf H. | Le Loarer, Francois | Italiano, Antoine

Edité par CCSD ; Nature Research -

International audience. Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion